Identification of MiR-125a as a Novel Plasma Diagnostic Biomarker for Chronic Lymphoblastic Leukemia

Ahmadvand, Mohammad; Eskandari, Mahsa; Khakpour, Golnaz; Pashaiefar, Hossein; Manoochehrabadi, Saba; Yaghmaie, Marjan; Montazer-Zohour, Mostafa; Naghavi, Anoosh

doi:10.7754/clin.lab.2018.180815

Cited by 4 publications

(3 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Ahmadvand study evaluated miR-125a as a biomarker in CLL patients; decreased miR-125 expression was reported in the patients [22]. Another study by Rigolin and associates was performed to determine the association between miR-125a expression and genetic abnormalities in CLL patients; they discovered that reduced miR-125a expression is associated with more genetic abnormalities in CLL individuals [23].…”

Section: Discussionmentioning

confidence: 99%

Evaluation of microRNA-223 and microRNA-125a expression association with STAT3 and Bcl2 genes in blood leukocytes of CLL patients: a case–control study

et al. 2021

View full text Add to dashboard Cite

Objective In chronic lymphocytic leukemia (CLL), lack of expression or dysregulation of some special miRs disrupts apoptosis of malignant cells; thereby miR expression can enhance cell proliferation, disease progression and decrease patient survival. Results 30 CLL patients and 20 healthy individuals participated in the study. RNA was extracted to evaluate the expression of miR-125, miR-223, BCL-2 and signal transducer and transcription 3 activator (STAT3) genes; quantitative Real Time- PCR (Q-RT-PCR) was performed. MiR-125a and miR-223 expression decreased in the patients compared to the control group (P-Value:0.001). BCL-2 and STAT3 which are the target genes of these two miRs, showed increased expression, in the patients compared to the control subjects (P-Value: 0.001 and P-Value: 0.64 respectively). A significant reverse relationship was found between miR-125a and BCl-2 expression and WBC count. Significantly, miR-223 expression was associated with smoking in patients (P-Value: 0.007). Also, these miRs may have regulatory effects by controlling white blood cell (WBC) production based on the inverse correlation with WBC count and hemoglobin (Hb) concentration. Finally, miR-223 can be used as a prognostic factor in CLL patients; miR-125a may be useful for evaluating the therapeutic approaches based on the inverse link with BCl-2.

show abstract

Section: Discussionmentioning

confidence: 99%

Evaluation of microRNA-223 and microRNA-125a expression association with STAT3 and Bcl2 genes in blood leukocytes of CLL patients: a case–control study

et al. 2021

View full text Add to dashboard Cite

show abstract

“…They found that miRNA 125a was reduced in breast cancer. Also, Ahmadvand et al, (2019) reported decreased miRNA 125 expression in CLL patients. Moreover, Rigolin et al, (2014) found that reduced miRNA 125a expression was associated with more genetic abnormalities in CLL patients.…”

Section: Research Articlementioning

confidence: 96%

Evaluation of miRNA 223/125a and COBLL1 Expressions and ROR-1 Levels as Reliable Markers in B- chronic Lymphocytic Leukemia

Hussein

Abdelazem

Abdelmoneem

et al. 2022

Asian Pac J Cancer Prev

View full text Add to dashboard Cite

Background: miRNA 223 /125a and Cordon-bleu Protein Like 1 (COBLL1) are novel biomarkers that can predict prognosis and guide treatment decisions in patients with chronic lymphocytic leukemia (CLL). Also, there is a growing interest in CLL monitoring based on flow cytometry of receptor tyrosine kinase-like orphan receptor-1 (ROR-1).Objective: This study aimed to evaluate the relationship between miRNA 223 /125a and COBLL1 expressions and ROR-1 expression in patients with CLL. Also, the study evaluated the relationship between the expression of these biomarkers with tumor staging and cancer progression. Methods: Our study included 40 patients newly diagnosed with B-CLL. In peripheral blood (PB), miRNA 223/125a and COBLL1 expressions were detected by real-time polymerase chain reaction (real-time PCR) and ROR-1 percentage was detected by flow cytometry before and after treatment. Results: High level of COBLL1 expression was statistically significantly associated with high ROR-1 percentage expression (P= 0.03). However, a high level of miRNA 223/125a expression was statistically significantly associated with low ROR-1 percentage expression (P=0.002). The sensitivity and specificity of ROR-1 as a predictor of high WBCs count after treatment were 96.6 and 81.1%, respectively. There was a statistically significant reduction of ROR-1 percentage after treatment compared to before treatment (P <0.001). Conclusion: ROR-1 percentage expression can be considered a possible prognostic predictor in CLL along with miRNA 223/125a and COBLL1 expressions. This can be explained by the significant correlation between ROR-1 and the studied molecular biomarkers; miRNA 223/125a and COBLL1. In addition, there was a significantly higher ROR-1 percentage in patients with higher WBC counts. Moreover, there was a significant reduction in ROR-1 percentage after treatment.

show abstract

“…Dysregulated levels of free circulating let-7e were observed in retinoblastoma, papillary thyroid carcinoma, lung, and prostate cancer ( 97 – 100 ), whereas altered levels of EV-bound let-7 characterize esophageal adenocarcinoma and lung cancer patients ( 101 , 102 ). miR-125a also represents a potential biomarker of treatment outcome for HCC patients ( 103 ) and altered levels of this miR were detected in certain blood malignancies ( 104 , 105 ), where they predicted response to chemotherapy, as demonstrated in patients with myelodysplastic syndromes ( 106 ). In serum, increased miR-146b levels correlate with papillary thyroid carcinoma recurrence ( 92 ), while elevated miR-146a is associated with higher overall response rate and survival in NSCLC ( 107 ).…”

Section: Introductionmentioning

confidence: 99%

microRNAs Shape Myeloid Cell-Mediated Resistance to Cancer Immunotherapy

et al. 2020

View full text Add to dashboard Cite

Immunotherapy with immune checkpoint inhibitors can achieve long-term tumor control in subsets of patients. However, its effect can be blunted by myeloid-induced resistance mechanisms. Myeloid cells are highly plastic and physiologically devoted to wound healing and to immune homeostasis maintenance. In cancer, their physiological activities can be modulated, leading to an expansion of pro-inflammatory and immunosuppressive cells, the myeloid-derived suppressor cells (MDSCs), with detrimental consequences. The involvement of MDSCs in tumor development and progression has been widely investigated and MDSC-induced immunosuppression is acknowledged as a mechanism hindering effective immune checkpoint blockade. Small non-coding RNA molecules, the microRNAs (miRs), contribute to myeloid cell regulation at different levels, comprising metabolism and function, as well as their skewing to a MDSC phenotype. miR expression can be indirectly induced by cancer-derived factors or through direct miR import via extracellular vesicles. Due to their structural stability and their presence in body fluids miRs represent promising predictive biomarkers of resistance, as we recently found by investigating plasma samples of melanoma patients undergoing immune checkpoint blockade. Dissection of the miR-driven involved mechanisms would pave the way for the identification of new druggable targets. Here, we discuss the role of these miRs in shaping myeloid resistance to immunotherapy with a special focus on immunosuppression and immune escape.

show abstract

Identification of MiR-125a as a Novel Plasma Diagnostic Biomarker for Chronic Lymphoblastic Leukemia

Cited by 4 publications

References 0 publications

Evaluation of microRNA-223 and microRNA-125a expression association with STAT3 and Bcl2 genes in blood leukocytes of CLL patients: a case–control study

Evaluation of microRNA-223 and microRNA-125a expression association with STAT3 and Bcl2 genes in blood leukocytes of CLL patients: a case–control study

Evaluation of miRNA 223/125a and COBLL1 Expressions and ROR-1 Levels as Reliable Markers in B- chronic Lymphocytic Leukemia

microRNAs Shape Myeloid Cell-Mediated Resistance to Cancer Immunotherapy

Contact Info

Product

Resources

About